INCYTE CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 57.05 USD | -0.95% |
|
+4.93% | -9.14% |
| May. 13 | Equities Close Mixed as Markets Weigh Consumer Inflation Survey | MT |
| May. 13 | Equities Close Mixed as Markets Parse Consumer Inflation Survey | MT |
ETFs positioned on Incyte Corporation
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.02% | 306 M€ | +5.71% | - | |
| 0.02% | 39 M€ | +5.65% | - | |
| 0.01% | 105 M€ | +3.32% | - | |
| 0.01% | 12 M€ | +13.22% | - | |
| 0.01% | 17 M€ | +2.84% | - | |
| 0.01% | 17 M€ | +4.20% | - | |
| 0.01% | 1 M€ | -.--% | ||
| 0.01% | 29 M€ | -.--% | - | |
| 0.01% | 322 M€ | +13.88% | - | |
| 0.01% | 34 M€ | +3.53% | - | |
| 0.01% | 54 M€ | +0.39% | - | |
| 0.01% | 6 M€ | +3.89% | ||
| 0.01% | 8 M€ | +0.60% | - | |
| 0.01% | 2 M€ | +3.16% | - | |
| 0.01% | 414 M€ | +11.88% | - | |
| 0.01% | 1,006 M€ | -.--% | - | |
| 0.01% | 756 M€ | +0.15% | - | |
| 1.20% | 129 M€ | +6.44% | - |
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows:
- product sales (85.6%);
- royalties (14.2%);
- income from research and cooperation agreements (0.2%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
57.6
USD
Average target price
73.35
USD
Spread / Average Target
+27.34%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -9.14% | 12.93B | |
| -2.47% | 89.37B | |
| +2.76% | 40.65B | |
| -12.32% | 32.81B | |
| +52.41% | 25B | |
| -17.39% | 15.29B | |
| -42.45% | 11.61B | |
| -10.48% | 11.49B | |
| +6.14% | 8.98B | |
| -7.72% | 8.23B |
- Stock Market
- Equities
- INCY Stock
- Funds and ETFs Incyte Corporation
